Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia; Department of Hematology and Medical Oncology, Emory University, Georgia Cancer Center for Excellence, Grady Memorial Hospital, Atlanta, Georgia.
Cancer. 2015 Feb 15;121(4):517-26. doi: 10.1002/cncr.29060. Epub 2014 Oct 24.
Trastuzumab-based chemotherapy has dramatically improved outcomes for patients with all stages of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Additional HER2-directed agents that have recently been approved are also expected to improve outcomes. Patients with small, lymph node-negative, HER2-positive breast cancers who are treated with trastuzumab-based chemotherapy demonstrate especially favorable responses, with 5-year recurrence rates of <5%. In this review, recent data regarding response rates among patients with early-stage HER2-positive breast cancer treated with trastuzumab-based chemotherapy are discussed. This review supports future studies of the possible omission of chemotherapy in a subset of patients with HER2-positive cancers, specifically those that coexpress hormone receptors.
曲妥珠单抗为基础的化疗显著改善了所有阶段的人表皮生长因子受体 2（HER2）阳性乳腺癌患者的预后。最近批准的其他针对 HER2 的药物也有望改善预后。接受曲妥珠单抗为基础的化疗治疗的小肿瘤、淋巴结阴性、HER2 阳性乳腺癌患者的反应尤其良好，5 年复发率<5%。在这篇综述中，讨论了接受曲妥珠单抗为基础的化疗治疗的早期 HER2 阳性乳腺癌患者的反应率的最新数据。这一综述支持了未来对 HER2 阳性癌症患者亚组（特别是同时表达激素受体的患者）可能省略化疗的研究。
